Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 15/20 | 0.60 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.51 |
| ▸ | RELA | Q04206 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068323 | 0.91 | ITGB1 (0.51) | ITGB1ITGA4NPC1NFKB1RAB9A | |
| SCHEMBL5068351 | 0.81 | ITGB1 (0.82) | ITGB1ITGA4RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5066847 | 0.75 | ITGB1 (0.80) | ITGB1ITGA4RAB9AMAPT | |
| SCHEMBL5068926 | 0.75 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL5066874 | 0.75 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL382910 | 0.71 | NPC1 (1.00) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL5071004 | 0.71 | ITGB1 (0.78) | ITGB1ITGA4MAPT | |
| SCHEMBL12692514 | 0.70 | NPC1 (0.74) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL12692434 | 0.69 | NPC1 (0.78) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL14626718 | 0.69 | NPC1 (0.70) | NPC1NFKB1RAB9ANFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | claimed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | ITGB1 5/4885ITGA4 2/4885NPC1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.